Philosys Anticipates FDA Approval for New Gmate® Blood Glucose Monitoring System
Published: Aug 03, 2012
"We are very excited to be close to FDA approval for our blood glucose monitoring technology and are preparing to bring this capability to the United States," said Jennifer Kupar, Operations Manager for Philosys. Gmate® SMART is the world's first "True Smartphone Meter." Given the dramatic rise of diabetes in the US and more tech savvy consumers, there is a growing demand for this medical technology that Philosys can meet."
Diabetic technology in the U.S. has not kept pace with the digital explosion of smartphones, tablets, and other digital devises. The US Centers for Disease Control predicts that as many as 1 in 3 U.S. adults could have diabetes by 2050. This increase could bring the average incidence of diabetes to more than 30 percent of the population.
"More and more U.S. consumers with diabetes are purchasing Smartphones daily," Kupar continued. "Gmate® is the perfect solution for diabetics seeking digital solutions to monitor their disease with the push of a button. We look forward to FDA approval of our revolutionary device this year."
The GmateTM blood glucose monitoring system is diabetic technology that makes life simple for consumers. GmateTM SMART is the smallest and most innovative meter in the world and works with the iPhone. For more information, visit http://www.gmate.com or Jennifer Kupar at email@example.com.
Philosys is a manufacturing company that specializes in medical, diagnostic and analytical instruments. The range of services provided covers the entire product cycle from concept through to manufacture. Philosys's philosophy is to develop cost-effective design and manufacturing solutions that satisfy our customer's vision. http://www.gmate.com
SOURCE Philosys, Inc.